Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.60 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.53 |
| ▸ | TAF1 | P21675 | 3/20 | 0.53 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.53 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.53 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22137642 | 1.00 | BRD4 (0.60) | BRD4BRD9TAF1CECR2TRIM24 | |
| SCHEMBL30781745 | 0.83 | BRD4 (0.57) | BRD4BRD9TAF1CECR2TRIM24 | |
| SCHEMBL22137588 | 0.80 | BRD4 (0.53) | BRD4BRD9TAF1CECR2TRIM24 | |
| SCHEMBL15067685 | 0.76 | BRD4 (1.00) | BRD4 | |
| SCHEMBL29745823 | 0.76 | BRD4 (1.00) | BRD4 | |
| SCHEMBL31590651 | 0.75 | BRD4 (0.66) | BRD4BRD9TAF1CECR2TRIM24 | |
| SCHEMBL17748894 | 0.75 | BRD4 (1.00) | BRD4BRD9TAF1CECR2TRIM24 | |
| SCHEMBL22137701 | 0.74 | ACVR1 (0.43) | BRD4 | |
| SCHEMBL24866050 | 0.73 | BRD4 (0.76) | BRD4BRD9TAF1CECR2 | |
| SCHEMBL29670525 | 0.73 | BRD4 (0.51) | BRD4BRD9TAF1CECR2TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | BRD4 4/4885BRD9 15/4885TAF1 23/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | BRD4 6/4885BRD9 22/4885TAF1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.